REPLIGEN CORP Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
REPLIGEN CORP (RGEN) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 181 shares for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-02-26
- REPLIGEN CORP incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-09-30 was 735.00 shares, a 35.01% decline year-over-year.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-06-30 was 701.00 shares, a 3.70% increase year-over-year.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-09-30 was 1.13K shares.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-06-30 was 676.00 shares.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 181.00 shares.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2021 was 1.25M shares, a 241.90% increase from fiscal 2020.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2020 was 366.53K shares, a 67.37% decline from fiscal 2019.
- REPLIGEN CORP incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2019 was 1.12M shares, a 0.01% increase from fiscal 2018.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | 181.00 shares 10-K · filed 2026-02-26 | |||||||
| 2023-09-30 | 735.00 shares 10-Q · filed 2023-10-31 | 776.00 shares 10-Q · filed 2023-10-31 | ||||||
| 2023-06-30 | 701.00 shares 10-Q · filed 2023-08-02 | 797.00 shares 10-Q · filed 2023-08-02 | ||||||
| 2022-09-30 | 1.13K shares 10-Q · filed 2023-10-31 | 1.50K shares 10-Q · filed 2023-10-31 | ||||||
| 2022-06-30 | 676.00 shares 10-Q · filed 2023-08-02 | 1.78K shares 10-Q · filed 2023-08-02 | ||||||
| 2021-12-31 | 1.25M shares 10-K · filed 2023-02-22 | |||||||
| 2021-03-31 | 8.00K shares 10-Q · filed 2021-05-04 | |||||||
| 2020-12-31 | 366.53K shares 10-K · filed 2023-02-22 | |||||||
| 2020-09-30 | 8.00K shares 10-Q · filed 2020-11-05 | 8.00K shares 10-Q · filed 2020-11-05 | ||||||
| 2019-12-31 | 1.12M shares 10-K · filed 2022-02-17 | 0.00 shares 10-K · filed 2020-02-26 | ||||||
| 2019-06-30 | 1.90M shares 10-Q · filed 2020-07-30 | 1.90K shares 10-Q · filed 2019-08-01 | 1.76M shares 10-Q · filed 2020-07-30 | 1.76K shares 10-Q · filed 2019-08-01 | ||||
| 2019-03-31 | 1.59M shares 10-Q · filed 2020-05-06 | 1.59K shares 10-Q · filed 2019-05-09 | ||||||
| 2018-12-31 | 1.12M shares 10-K · filed 2021-02-24 | 1.12K shares 10-K · filed 2019-03-01 | ||||||
| 2018-09-30 | 1.35K shares 10-Q · filed 2019-10-31 | 1.35M shares 10-Q · filed 2018-11-01 | 892.00 shares 10-Q · filed 2019-10-31 | 892.18K shares 10-Q · filed 2018-11-01 | ||||
| 2018-06-30 | 792.00 shares 10-Q · filed 2019-08-01 | 791.80K shares 10-Q · filed 2018-08-02 | 578.00 shares 10-Q · filed 2019-08-01 | 578.13K shares 10-Q · filed 2018-08-02 | ||||
| 2018-03-31 | 316.00 shares 10-Q · filed 2019-05-09 | 315.76K shares 10-Q · filed 2018-05-08 | ||||||
| 2017-12-31 | 474.92K shares 10-K · filed 2020-02-26 | |||||||
| 2017-09-30 | 842.21K shares 10-Q · filed 2018-11-01 | 496.40K shares 10-Q · filed 2018-11-01 | ||||||
| 2017-06-30 | 559.58K shares 10-Q · filed 2018-08-02 | 286.99K shares 10-Q · filed 2018-08-02 | ||||||
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-09 | 0.00 shares 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |